171 related articles for article (PubMed ID: 31100326)
1. MMP targeting in the battle for vision: Recent developments and future prospects in the treatment of diabetic retinopathy.
Drankowska J; Kos M; Kościuk A; Marzęda P; Boguszewska-Czubara A; Tylus M; Święch-Zubilewicz A
Life Sci; 2019 Jul; 229():149-156. PubMed ID: 31100326
[TBL] [Abstract][Full Text] [Related]
2. Targeting Matrix Metalloproteinases for Diabetic Retinopathy: The Way Ahead?
Solanki A; Bhatt LK; Johnston TP; Prabhavalkar KS
Curr Protein Pept Sci; 2019; 20(4):324-333. PubMed ID: 30215334
[TBL] [Abstract][Full Text] [Related]
3. Regulation of Matrix Metalloproteinase in the Pathogenesis of Diabetic Retinopathy.
Kowluru RA; Mishra M
Prog Mol Biol Transl Sci; 2017; 148():67-85. PubMed ID: 28662829
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9.
Kowluru RA; Zhong Q; Santos JM
Expert Opin Investig Drugs; 2012 Jun; 21(6):797-805. PubMed ID: 22519597
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy.
Salzmann J; Limb GA; Khaw PT; Gregor ZJ; Webster L; Chignell AH; Charteris DG
Br J Ophthalmol; 2000 Oct; 84(10):1091-6. PubMed ID: 11004090
[TBL] [Abstract][Full Text] [Related]
6. [The role of matrix metalloproteinases in the pathogenesis of diabetes mellitus and progression of diabetes retinopathy].
Naduk-Kik J; Hrabec E
Postepy Hig Med Dosw (Online); 2008 Sep; 62():442-50. PubMed ID: 18772849
[TBL] [Abstract][Full Text] [Related]
7. Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy.
Jacqueminet S; Ben Abdesselam O; Chapman MJ; Nicolay N; Foglietti MJ; Grimaldi A; Beaudeux JL
Clin Chim Acta; 2006 May; 367(1-2):103-7. PubMed ID: 16426593
[TBL] [Abstract][Full Text] [Related]
8. Circulating matrix modulators (MMP-9 and TIMP-1) and their association with severity of diabetic retinopathy.
Jayashree K; Yasir M; Senthilkumar GP; Ramesh Babu K; Mehalingam V; Mohanraj PS
Diabetes Metab Syndr; 2018 Nov; 12(6):869-873. PubMed ID: 29752166
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-2 expression and apoptogenic activity in retinal pericytes: implications in diabetic retinopathy.
Yang R; Liu H; Williams I; Chaqour B
Ann N Y Acad Sci; 2007 Apr; 1103():196-201. PubMed ID: 17332085
[TBL] [Abstract][Full Text] [Related]
10. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects.
Levin M; Udi Y; Solomonov I; Sagi I
Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt A):1927-1939. PubMed ID: 28636874
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer.
Radisky ES; Raeeszadeh-Sarmazdeh M; Radisky DC
J Cell Biochem; 2017 Nov; 118(11):3531-3548. PubMed ID: 28585723
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: an overview.
Chaudhary AK; Pandya S; Ghosh K; Nadkarni A
Mutat Res; 2013; 753(1):7-23. PubMed ID: 23370482
[TBL] [Abstract][Full Text] [Related]
13. Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects.
Li W; Saji S; Sato F; Noda M; Toi M
Int J Biol Markers; 2013 Jun; 28(2):117-30. PubMed ID: 23787494
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinases: potential therapeutic target for diabetic neuropathic pain.
Kuhad A; Singh P; Chopra K
Expert Opin Ther Targets; 2015 Feb; 19(2):177-85. PubMed ID: 25243524
[TBL] [Abstract][Full Text] [Related]
15. Differential expression and localization of human tissue inhibitors of metalloproteinases in proliferative diabetic retinopathy.
Abu El-Asrar AM; Ahmad A; Bittoun E; Siddiquei MM; Mohammad G; Mousa A; De Hertogh G; Opdenakker G
Acta Ophthalmol; 2018 Feb; 96(1):e27-e37. PubMed ID: 28391660
[TBL] [Abstract][Full Text] [Related]
16. [Structure Activity Relationship Study of Polymethoxylated Flavones Targeted Retinal Müller Cells for Prevention of Retinal Diseases].
Miyata Y
Yakugaku Zasshi; 2021; 141(1):41-45. PubMed ID: 33390446
[TBL] [Abstract][Full Text] [Related]
17. Role of matrix metalloproteinase-9 in the development of diabetic retinopathy and its regulation by H-Ras.
Kowluru RA
Invest Ophthalmol Vis Sci; 2010 Aug; 51(8):4320-6. PubMed ID: 20220057
[TBL] [Abstract][Full Text] [Related]
18. Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability.
Müller A; Krämer SD; Meletta R; Beck K; Selivanova SV; Rancic Z; Kaufmann PA; Vos B; Meding J; Stellfeld T; Heinrich TK; Bauser M; Hütter J; Dinkelborg LM; Schibli R; Ametamey SM
Nucl Med Biol; 2014 Aug; 41(7):562-9. PubMed ID: 24853402
[TBL] [Abstract][Full Text] [Related]
19. Novel Matrix Metalloproteinase-9 (MMP-9) Inhibitors in Cancer Treatment.
Rashid ZA; Bardaweel SK
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569509
[TBL] [Abstract][Full Text] [Related]
20. Interrelationship between activation of matrix metalloproteinases and mitochondrial dysfunction in the development of diabetic retinopathy.
Santos JM; Tewari S; Lin JY; Kowluru RA
Biochem Biophys Res Commun; 2013 Sep; 438(4):760-4. PubMed ID: 23891690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
